ArticleThe Prostate2010
Association of CD14 variant with prostate cancer in African American men.
Article in The Prostate, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Pooled it
- Impacts of Interleukin-10 Promoter Genotypes on Prostate Cancer.Life (Basel, Switzerland) · 2024Article
- Article
- Dual impacts of mesenchymal stem cell-derived exosomes on cancer cells: unravelling complex interactions.Journal of cell communication and signaling · 2023Review
- Emerging role of exosomes in the pathology of chronic obstructive pulmonary diseases; destructive and therapeutic properties.Stem cell research & therapy · 2022Review
- Geographic Distribution of Racial Differences in Prostate Cancer Mortality.JAMA network open · 2020Article
- Genetic Polymorphisms in IL-10 Promoter Are Associated With Smoking and Prostate Cancer Risk in African Americans.Anticancer research · 2020Article
- Racial disparities and considerations for active surveillance of prostate cancer.Translational andrology and urology · 2018Review
- The Pathologic Role of Toll-Like Receptor 4 in Prostate Cancer.Frontiers in immunology · 2018Review
- Exosomes-based biomarker discovery for diagnosis and prognosis of prostate cancer.Frontiers in bioscience (Landmark edition) · 2017Review
- Vitamin D and Immune Response: Implications for Prostate Cancer in African Americans.Frontiers in immunology · 2016Review
- Methylome-wide Sequencing Detects DNA Hypermethylation Distinguishing Indolent from Aggressive Prostate Cancer.Cell reports · 2015Article
- Incidence of prostate and urological cancers in England by ethnic group, 2001-2007: a descriptive study.BMC cancer · 2015Article
- Prostate cancer: from the pathophysiologic implications of some genetic risk factors to translation in personalized cancer treatments.Cancer gene therapy · 2014Review
- The -159C/T polymorphism in the CD14 gene and cancer risk: a meta-analysis.OncoTargets and therapy · 2013Article
- Article
- Molecular classification of prostate cancer using curated expression signatures.Proceedings of the National Academy of Sciences of the United States of America · 2011Article
- Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer.The Prostate · 2011Review
- LBP and CD14 polymorphisms correlate with increased colorectal carcinoma risk in Han Chinese.World journal of gastroenterology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundAfrican American men have the highest rates of prostate cancer worldwide, and immunogenetic studies suggest that people of African descent have increased susceptibility to diseases of inflammation. Since genetic susceptibility is an etiological factor in prostate cancer, we hypothesize that sequence variants in the promoter region of the CD14 gene that regulate inflammation may modify individual susceptibility to this disease.
methodsThe CD14 promoter was screened for single-nucleotide polymorphisms (SNPs) using dHPLC. One variant, -260 C>T (rs2569190), was genotyped via restriction digest in all study participants (264 cases and 188 controls). The association of disease status and the polymorphism was analyzed by unconditional logistic regression. Odds ratios with 95% confidence intervals were calculated, stratifying by ethnicity and adjusting for age. Two-sided P-values of < or =0.05 were considered as statistically significant.
resultsEleven variants (four novel) were identified in the promoter region of CD14. A marginal association between the C genotypes (C/C + C/T) and prostate cancer was found (P = 0.07). When stratified by age, among men > or =55 years of age, the C genotypes were significantly associated with prostate cancer (P < 0.05). When stratified by self-reported ethnicity, African American males who had the C genotypes were at a higher risk for prostate cancer (P < 0.05).
conclusionsThis is the first study to show an association between the C genotypes of the CD14 (-260) variant and prostate cancer which supports the hypothesis that genetic variation in the inflammatory process can contribute to prostate cancer susceptibility in African American men.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.